List of Excipients in Branded Drug LOTRIMIN ULTRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer Healthcare LLC	LOTRIMIN ULTRA	butenafine hydrochloride	11523-0082	BENZYL ALCOHOL
Bayer Healthcare LLC	LOTRIMIN ULTRA	butenafine hydrochloride	11523-0082	CETETH-23
Bayer Healthcare LLC	LOTRIMIN ULTRA	butenafine hydrochloride	11523-0082	CETYL ALCOHOL

Last updated: September 23, 2026

LOTRIMIN ULTRA is a mature OTC topical antifungal based on butenafine hydrochloride 1%. Its commercial opportunity is primarily in generic substitution, differentiated vehicle design, private-label distribution, and adjacent dermatology products rather than new-chemical-entity exclusivity. The current cream uses a conventional oil-in-water system with fatty alcohols, ester emollients, preservatives, and water. Formulation developers can compete through better spreadability, lower residue, improved tolerability, lower-cost manufacturing, and alternative dosage forms.

Lotrimin Ultra Excipient Strategy and Commercial Opportunities

What is Lotrimin Ultra and which active ingredient does it contain?

Lotrimin Ultra is an OTC topical antifungal cream containing butenafine hydrochloride 1% as the active ingredient. Butenafine is a benzylamine antifungal used for conditions including athlete's foot, jock itch, and ringworm.

The product is distinct from standard Lotrimin products that may contain clotrimazole or other antifungal ingredients. Its formulation objective is delivery of butenafine into the stratum corneum while maintaining acceptable cosmetic properties and shelf stability.

Product attribute	Lotrimin Ultra
Active ingredient	Butenafine hydrochloride
Strength	1%
Dosage form	Topical cream
Route	Cutaneous
U.S. regulatory category	OTC topical antifungal
Primary indications	Tinea pedis, tinea cruris, and tinea corporis
Principal commercial competitors	Generic butenafine 1% creams, terbinafine 1% products, clotrimazole products, miconazole products
Primary formulation challenge	Delivering a lipophilic antifungal in a stable, cosmetically acceptable semisolid

The U.S. product labeling identifies inactive ingredients that include benzyl alcohol, cetyl alcohol, cetyl esters wax, isopropyl myristate, purified water, sodium benzoate, and stearyl alcohol. Formulations may differ by manufacturer, market, and packaging configuration, so the marketed label should control any regulatory or substitution analysis. (U.S. National Library of Medicine, n.d.)

What excipients are used in Lotrimin Ultra?

The excipient system is a conventional dermatological cream platform.

Excipient	Likely formulation function	Commercial relevance
Benzyl alcohol	Preservative, solvent, and antimicrobial support	Can affect odor, tolerability, and pediatric positioning
Cetyl alcohol	Consistency agent and emulsion stabilizer	Controls viscosity, structure, and skin feel
Cetyl esters wax	Emollient and consistency modifier	Improves cream body and reduces greasiness
Isopropyl myristate	Emollient and penetration-supporting vehicle	Improves spreadability but can influence irritation and comedogenicity
Purified water	Aqueous phase	Supports oil-in-water cream architecture
Sodium benzoate	Preservative	Requires suitable pH and preservative-system control
Stearyl alcohol	Thickener, emollient, and stabilizer	Supports texture, viscosity, and phase stability

The excipients do not generally provide the primary antifungal effect. Their value lies in controlling drug release, skin partitioning, water loss, application comfort, preservative performance, and physical stability.

How does the Lotrimin Ultra vehicle support butenafine delivery?

Butenafine hydrochloride is a lipophilic topical antifungal despite its salt form. A cream vehicle must balance two competing requirements:

1. Keep the active sufficiently dispersed or solubilized during manufacture and storage.
2. Release the active after application so it can partition into the outer skin layers.

Isopropyl myristate and fatty alcohols contribute to the oil phase and can influence drug partitioning. The water phase provides a non-occlusive cream profile that is generally more acceptable than a petrolatum-heavy ointment. Cetyl and stearyl alcohols increase viscosity and help maintain emulsion structure.

A replacement formulation that increases oil content may improve occlusion and residence time but can create a greasy after-feel. A formulation with a higher aqueous fraction may spread more easily but can reduce residence time, increase drying, or require stronger preservation controls.

Which excipient strategies could improve Lotrimin Ultra?

The most commercially relevant strategy is not simply to replace one excipient. It is to optimize the complete vehicle for a specific consumer or channel need.

Lower-grease cream

A lower-residue cream could compete with the existing product on cosmetic acceptability. Potential approaches include:

• Reducing the level of heavy waxes.
• Using lighter emollient esters.
• Rebalancing cetyl and stearyl alcohol.
• Introducing silicone-based emollients.
• Improving droplet-size distribution during homogenization.

The main development risks are lower viscosity, phase separation, altered drug release, and loss of preservative robustness.

Fast-spreading formulation

A fast-spreading formulation could appeal to consumers treating large areas or applying the product between daily activities. Isopropyl myristate already supports spreadability, but alternative ester systems may provide a less oily profile.

Candidate excipient classes include medium-chain triglycerides, C12-C15 alkyl benzoates, ethoxylated esters, and selected volatile or nonvolatile silicones. Any replacement must be assessed for irritation, sensitization, drug solubility, and impact on permeation.

Low-irritation formulation

Benzyl alcohol is a functional preservative and solvent, but some consumers may prefer products without benzyl alcohol or with a reduced preservative burden. Potential strategies include:

• Alternative preservative systems.
• Preservative-free single-use packaging.
• Airless pumps that reduce microbial ingress.
• Lower-water systems.
• pH optimization for sodium benzoate performance.

Preservative removal is not automatically an improvement. A cream with water and repeated consumer contact requires validated antimicrobial protection under USP <51> or equivalent testing.

Noncomedogenic and sensitive-skin positioning

An excipient system with reduced fragrance, reduced sensitizer exposure, and a lighter emollient profile could support sensitive-skin positioning. This creates a differentiated claim platform, although claims must be supported by appropriate testing and must remain consistent with OTC labeling requirements.

What formulations could compete with Lotrimin Ultra?

The main dosage-form opportunity is to create consumer-specific alternatives rather than a direct copy.

Dosage form	Potential commercial advantage	Development barrier
Cream	Familiar, broad consumer acceptance	Crowded generic market
Gel	Rapid drying and low residue	Drug solubility and drying-related irritation
Spray or solution	Convenient for feet and large areas	Dose uniformity and delivery loss
Foam	Fast application and cosmetic appeal	Propellant, valve, and packaging complexity
Ointment	Higher occlusion and residence time	Greasy feel and lower consumer acceptance
Hydrogel	Cooling sensation and low oil content	Active release and preservative design
Wipe or film	Portable, unit-dose application	Drug loading, drying, and packaging stability

A gel or spray could create more commercial separation than another conventional cream. The tradeoff is higher technical and regulatory complexity. A generic cream can usually be developed with lower capital requirements and a shorter scale-up path.

What regulatory pathway applies to a butenafine 1% product?

Butenafine 1% topical antifungal products are generally positioned within the FDA OTC topical antifungal framework. FDA’s OTC antifungal monograph identifies permitted active ingredients, concentrations, indications, labeling requirements, and directions for use. A product that conforms to the applicable monograph conditions may avoid the full new-drug application pathway required for a novel unmonographized product. (U.S. Food and Drug Administration, 2022)

Regulatory assessment must address:

• Active ingredient identity and concentration.
• Dosage form and route.
• Required antifungal indications.
• Required warnings and directions.
• Manufacturing controls.
• Microbial limits and preservative effectiveness.
• Stability through labeled shelf life.
• Container-closure compatibility.
• Drug release and product performance.
• Labeling consistency across package sizes.

The formulation cannot rely on excipient novelty to bypass active-ingredient or labeling requirements. A new vehicle may create product-performance and comparability questions even when the active ingredient and strength remain unchanged.

What is the FDA status of Lotrimin Ultra?

Lotrimin Ultra is marketed as an OTC topical antifungal product. The relevant FDA framework is the OTC topical antifungal monograph and associated labeling requirements, rather than a biologic or biosimilar pathway. FDA’s Drug Facts labeling rules govern consumer-facing information, including active ingredient, purpose, uses, warnings, directions, and inactive ingredients. (U.S. Food and Drug Administration, 2023)

A biosimilar analysis is not relevant because butenafine is a small-molecule active ingredient and Lotrimin Ultra is not a biologic.

What patents protect Lotrimin Ultra?

The primary commercial barrier for a butenafine 1% cream is unlikely to be a current composition-of-matter patent on butenafine. The active ingredient has been commercially established for decades, and the product competes in a mature OTC category.

Potential IP layers include:

• Historical patents covering butenafine or related benzylamine compounds.
• Formulation patents covering specific cream systems.
• Manufacturing-process patents.
• Packaging or delivery-device patents.
• Trademark rights covering the Lotrimin Ultra brand.
• Trade dress and consumer-brand assets.

A competitor should conduct a current freedom-to-operate search across U.S. Patent and Trademark Office records, FDA submissions, and litigation databases before relying on the absence of an identified formulation patent. Patent status can differ by jurisdiction and by product presentation.

Are Paragraph IV challenges relevant?

Paragraph IV litigation is generally associated with abbreviated new drug applications that challenge listed patents for an approved drug. A monograph-compliant OTC product does not necessarily follow the same patent-certification pathway as an ANDA product. The commercial strategy therefore depends on the selected regulatory route.

If a sponsor pursues an NDA-based or other approval pathway tied to listed patents, patent certifications and litigation risks may arise. For a monograph-compliant product, the principal risks are more likely to involve formulation patents, trademarks, trade dress, and regulatory compliance than a classic Paragraph IV launch dispute.

How strong is the patent estate for Lotrimin Ultra?

The estate should be viewed as moderate to weak for blocking generic cream entry, but potentially stronger around brand assets and differentiated delivery systems.

IP category	Likely blocking value
Butenafine active ingredient	Low for current market entry because of product maturity
Conventional cream composition	Low to moderate, depending on claim scope and expiration
Specialized low-irritation or delivery formulation	Moderate if claims are narrow and technically supported
Packaging or applicator	Low to moderate
Lotrimin Ultra trademark	High against confusing brand presentation
Trade dress	Moderate, subject to proof and scope
Manufacturing know-how	Moderate as a practical barrier, even without patent protection

The strongest defensible opportunity is a technically distinct formulation with measurable performance advantages, not a routine substitution of one fatty alcohol for another.

When does Lotrimin Ultra lose exclusivity?

Lotrimin Ultra does not have a single exclusivity date comparable to a newly approved prescription drug. Market protection is distributed across regulatory status, brand recognition, trademark rights, formulation patents, manufacturing know-how, and retail placement.

The active ingredient and therapeutic category are mature. Generic and private-label competition can therefore enter if products meet the applicable OTC regulatory requirements and avoid enforceable patent, trademark, and trade-dress rights.

What is the Orange Book status of Lotrimin Ultra?

The Orange Book is primarily used for approved prescription and certain approved nonprescription drug products with FDA approval histories. A current Orange Book listing should not be assumed solely from the Lotrimin Ultra brand name. Product-specific verification is required because OTC monograph products, approved OTC products, and prescription products can have different FDA records and listing treatment. (U.S. Food and Drug Administration, n.d.)

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target four opportunity areas.

Premium vehicle platforms

Suppliers can offer prequalified cream bases optimized for:

• Low greasiness.
• High spreadability.
• Sensitive skin.
• Rapid drying.
• Improved preservative performance.
• Compatibility with butenafine and related lipophilic antifungals.

The value proposition is faster development and reduced formulation risk for private-label manufacturers.

Generic and private-label supply

Retailers and consumer-health companies may seek store-brand alternatives to branded topical antifungals. A compliant butenafine cream with stable supply, efficient filling, and attractive packaging can compete on price without requiring novel pharmacology.

Adjacent antifungal products

A single vehicle platform could support other actives, including clotrimazole, miconazole, tolnaftate, or terbinafine, subject to active-specific compatibility and regulatory requirements. A modular base can reduce development cost across multiple SKUs.

Manufacturing and packaging optimization

Commercial gains can come from:

• High-speed tube filling.
• Aluminum or laminate tube compatibility.
• Airless pump packaging.
• Improved bulk handling.
• Reduced batch cycle time.
• Lower preservative and water-activity risk.
• Better control of emulsion particle size.

Manufacturing know-how can be difficult for competitors to replicate even when the final ingredient list is public.

Which companies are challenging Lotrimin Ultra?

The competitive set includes manufacturers of generic butenafine 1% cream and suppliers of alternative OTC antifungal actives. Direct and indirect competitors include products based on terbinafine, clotrimazole, miconazole, and tolnaftate.

Competition is shaped by:

• Retail price.
• Treatment duration.
• Consumer recognition.
• Product availability.
• Application feel.
• Package convenience.
• Retailer private-label strategy.
• Claims permitted on the Drug Facts label.

Terbinafine products can compete on shorter labeled treatment courses for some indications. Clotrimazole and miconazole products often compete through lower price and broad retail availability. Butenafine products can differentiate through brand association and vehicle quality.

What generic launch risks exist?

A generic or private-label launch faces five principal risks:

1. Regulatory mismatch: The product may fall outside monograph conditions because of dosage form, labeling, active concentration, or claims.
2. Formulation instability: Emulsion separation, viscosity drift, crystallization, or preservative failure can delay launch.
3. Performance uncertainty: A visually similar cream may release butenafine differently from the reference product.
4. Trademark exposure: Packaging that resembles Lotrimin Ultra too closely can create brand and trade-dress risk.
5. Retail economics: A low-priced product may not achieve sufficient margin after manufacturing, testing, distribution, and retailer deductions.

The lowest-risk launch is usually a conventional butenafine 1% cream using well-characterized excipients and a clearly differentiated package. The highest-upside launch is a cosmetically superior gel, spray, foam, or low-irritation cream with evidence-backed consumer benefits.

Key Takeaways

• Lotrimin Ultra contains butenafine hydrochloride 1% in a conventional topical cream.
• Its listed excipients support emulsion stability, viscosity, spreadability, preservation, and skin feel.
• The strongest formulation opportunities are low-grease, sensitive-skin, fast-spreading, and alternative-delivery products.
• Butenafine is a mature small-molecule antifungal, so biosimilar risk is not relevant.
• Current commercial protection is more likely to depend on trademarks, formulation claims, packaging, manufacturing know-how, and retail strength than on active-ingredient exclusivity.
• A monograph-compliant generic cream offers the lowest development risk.
• A gel, spray, foam, or unit-dose system offers greater differentiation but higher technical and regulatory risk.
• Excipient suppliers can create value through ready-to-use vehicle platforms and multi-active antifungal bases.

FAQs About Lotrimin Ultra Excipient and Commercial Strategy

Can benzyl alcohol be removed from a butenafine cream?

Yes, but removal requires a redesigned preservation and packaging strategy. The replacement must maintain microbial protection, stability, tolerability, and regulatory compliance.

Is isopropyl myristate essential to Lotrimin Ultra?

No. It is a functional emollient and spreadability aid, but alternative ester, silicone, or hydrocarbon systems may be evaluated. Replacement can change drug release, skin feel, and irritation potential.

Can a private-label product use the same Lotrimin Ultra excipients?

Ingredient identity alone usually does not establish infringement. The sponsor must still assess formulation patents, trade dress, trademarks, regulatory requirements, and product-performance obligations.

Is a butenafine gel commercially superior to a cream?

Not automatically. A gel may provide faster drying and less residue, but it can create challenges in drug solubility, skin irritation, drying, and dose uniformity. Its value depends on demonstrable consumer and performance advantages.

What is the most attractive excipient opportunity around butenafine?

A low-residue, low-irritation cream or gel with validated stability and improved application feel offers the strongest balance between technical feasibility and commercial differentiation.

References

1. U.S. Food and Drug Administration. (2022). Topical antifungal drug products for over-the-counter human use: Final monograph. Code of Federal Regulations, 21 C.F.R. Part 333, Subpart C.

2. U.S. Food and Drug Administration. (2023). Over-the-counter human drugs: Labeling requirements. Code of Federal Regulations, 21 C.F.R. Part 201.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

4. U.S. National Library of Medicine. (n.d.). DailyMed: Lotrimin Ultra butenafine hydrochloride cream labeling. https://dailymed.nlm.nih.gov/